Robert Nelsen - Feb 8, 2024 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Signature
/s/ Mark McDonnell, Attorney-in-Fact for Robert Nelsen
Stock symbol
SANA
Transactions as of
Feb 8, 2024
Transactions value $
$9,999,996
Form type
4
Date filed
2/12/2024, 05:46 PM
Previous filing
Sep 8, 2023
Next filing
Feb 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SANA Common Stock Purchase $2M +364K +3.53% $5.50 10.7M Feb 8, 2024 See Footnote F1, F3, F7
transaction SANA Common Stock Purchase $4M +727K +6.21% $5.50 12.4M Feb 8, 2024 See Footnote F4, F6, F7
transaction SANA Common Stock Purchase $4M +727K +6.21% $5.50 12.4M Feb 8, 2024 See Footnote F5, F6, F7
holding SANA Common Stock 10.3M Feb 8, 2024 See Footnote F2, F3, F7
holding SANA Common Stock 1.35K Feb 8, 2024 Direct F8
holding SANA Common Stock 12.5K Feb 8, 2024 See Footnote F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
F2 Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
F3 ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. In addition to the Reporting Person, Keith Crandell and Clinton Bybee are also managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the other AVP IX MDs have filed a separate Form 4 and disclaim beneficial ownership except to to the extent of any pecuniary interest therein
F4 Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
F5 Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
F6 ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. In addition to the Reporting Person, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the other AVP X Committee Members have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein.
F7 The Reporting Person is also an AVP IX MD and an AVP X Committee Member and may be deemed to beneficially own the shares held by ARCH IX, ARCH IX Overage, ARCH X, and ARCH X Overage. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any.
F8 Consists of fully vested restricted stock units.
F9 Shares held by Enzo Family Trust of 2015. The Reporting Person's children are the beneficiaries of Enzo Family Trust of 2015.